Heather HUET,Seth ETTENBERG,Django SUSSMAN,Tooba CHEEMA,Taylor HICKMAN,Katie O'CALLAGHAN,Maureen RYAN
申请号：
US16486741
公开号：
US20190381171A1
申请日:
2018.02.16
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig)； a transmembrane domain； optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
